Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reissue Patent
2009-12-11
2010-12-28
Kosar, Andrew D (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S317000, C530S330000, C530S333000, C514S021100
Reissue Patent
active
RE042013
ABSTRACT:
The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.
REFERENCES:
patent: 6548501 (2003-04-01), Hakkinen
patent: 6852722 (2005-02-01), Hakkinen
patent: WO 01/25257 (2001-04-01), None
patent: WO 01/92292 (2001-12-01), None
patent: WO 2004/111077 (2004-12-01), None
patent: WO 2005/012331 (2005-02-01), None
patent: WO 2005/012332 (2005-02-01), None
C. W. Thronber. Chem. Soc. Rev. (1979) 8(4), pp. 563-580.
Examination Report corresponding to European Patent Application No. 05785185.9 dated Jun. 11, 2010.
Ahnfelt-Ronne et al. “Do Growth Hormone-Releasing Peptides Act as Ghrelin Secretagogues?”Endocrine14(1): 133-135 (2001).
Arcadi et al. “Electrophilic Cyclization of o-Acetoxy- and o-Benzyloxyalkynylpyridines: An Easy Entry into 2, 3-Disubsituted Furopyridines”Organic Letters4(14): 2409-2412 (2002).
Ariyasu et al. “Stomach is a Major Source of Circulating Ghrelin, and Feeding State Determines Plasma Ghrelin-Like Immunoreactivity Levels in Humans”The Journal of Clinical Endocrinology & Metabolism86(10);: 4756-4758 (2001).
Arvat et al. “Growth Hormone-Releasing Hormone and Growth Hormone Secretagogue-Receptor Ligands”Endocrine14(1): 35-43 (2001).
Backes et al. “Solid Support Linker Strategies”Current Opinion in Chemical Biology1: 86-93 (1997).
Baig et al. “Postoperative Ileus: A Review”Diseases of the Colon & Rectum47: 516-526 (2002).
Baldanzi et al. “Ghrelin and des-acyl Ghrelin Inhibit Cell Death in Cardiomyocytes and Endothelial Cells through ERK1/2 and PI 3-kinase/AKT”The Journal of Cell Biology159(6): 1029-1037 (2002).
Baldwin et al. “Symbiotic Approach to Drug Design: Antihypertensive β-Adrenergic Blocking Agents”Journal of Medicinal Chemistry22(11): 1284-1290 (1979).
Banks et al. “Extent and Direction of Ghrelin Transport Across the Blood-Brain Barrier is Determined by its Unique Primary Structure”The Journal of 3 Pharmacology and Experimental Therapeutics302: 822-827 (2002).
Barreiro et al. “Developmental, State-Specific, and Hormonally Regulated Expression of Growth Hormone Secretagogue Receptor Messenger RNA in Rat Testis”Biology of Reproduction68: 1631-1640 (2002).
Barth et al. “Tailoring Ultraresins Based on the Cross-Linking of Polyethylene Imines. Comparative Investigation of the Chemical Composition, the Swelling, the Mobility, the Chemical Accessibility, and the Performance in Solid-Phase Synthesis of Very High Loaded Resins”Journal of Combinatorial Chemistry6: 340-349 (2004).
Bedendi et al. “cardiac Effects of Ghrelin and its Endogenous derivatives des-octanoyl Ghrelin and des-Gln14-ghrelin”European Journal of Pharmacology4768 87-95 (2003).
Bednarek et al. “Structure-Function Studies on the New Growth Hormone-Releasing Peptide, Ghrelin: Minimal Sequence of Ghrelin Necessary for Activation of Growth Hormone Secretagogue Receptor 1a”Journal of Medicinal Chemistry43: 4370-4376 (2000).
Birr et al. “Der α.α-Dimethyl-3.5-dimethoxybenzyloxycarbonyl (Ddz)-Rest, eine photo- und säurelabile Stickstoff-Schutzgruppe für die Peptidehemie”Liebigs Ann Chem763: 162-172 (1972).
Bossharth et al. “Palladium-Mediated Three-Component Sythesis of Furo[2,3-b]pyridones by One=Pot Coupling of 3-Iodopyridones, Alkynes, and Organic halides”Organic Letters5(14): 2441-2444 (2003).
Bowers “Growth Hormone Releasing Peptides: Physiology and Clinical Applications”Current Opinion in Endocrinology & Diabetes7: 168-174 (2000).
Bowers et al. “Structure-Activity Relationships of a Synthetic Pentapeptide that Specifically Releases Growth Hormonein Vitro” Endocrinology106(3): 663-667 (1980).
Broglio et al. “Endocrine and Non-Edocrine Actions of Ghrelin”Hormone Research59: 109-117 (2003).
Camanni et al. “Growth Hormone-Releasing Peptides and Their Analogs”Frontiers in Neuroendocrinology19: 47-72 (1998).
Camilleri “Advances in Diabetic Gastroparesis” Reviews in Gastroenterological Disorders 2(2): 47-56 (2002).
Carlini et al. “Ghrelin Increases Anxiety-Like Behavior and Memory Retention in Rats”Biochemical and Biophysical Research Communications299: 739-743 (2002).
Carpino et al. “recent Developments in Ghrelin Receptor (GHS-R1a) Agonists and Antagonists”Expert Opinion in Ther. Patents12(11): 1599-1618 (2002).
Carreira et al. “Agonist-Specific Coupling of Growth Hormone Secretagogue Receptor Type 1a to Different Intracellular Signaling Systems”Neuroendocrinology79: 13-25 (2004).
Casanueva et al. “Ghrelin: The Link Connection Growth with Metabolism and Energy Homeostatis”Reviews in Endocrine & Metabolic Disorders3: 325-338 (2002).
Cassoni et al. “Expression of Ghrelin and Biological Activity of Specific Receptors for Ghrelin and des-acyl Ghrelin in Human Prostate Neoplasms and Related Cell Lines”European Journal of Endocrinology150: 173-184 (2004).
Chan et al. “Identification and Functional Characterization of Two Alternatively Spliced Growth Hormone Secretagogue Receptor Transcripts from the Pituitary of Black SeabreamAcanthopagrus schlegeli” Molecular and Cellular Endocrinology241: 81-95 (2004).
Chang et al. “A Highly Efficient and practical Synthesis of Chromene Derivatives using Ring-Closing Olefin Metathesis”Journal of Organic Chemistry63: 864-866 (1998).
Chang et al. “Activity of a Novel Nonpeptidyl Growth Hormone Secretagogue, L-700, 653, in Swine”Endocrinology136(3): 1065-1071 (1995).
Cheng et al. “The Synergistic Effects of His-D-Trp-Ala-Trp-D-Phe-Lys-NH2on Growth Hormone (GH)-Releasing Factor-Stimulated GH Release and Intracellular Adenosine 3′, 5′-Monophosphate Accumulation in Rat Primary Pituitary Cell Culture”Endocrinology124(6): 2791-2798 (1989).
Comins et al. “N- vs. O-Alkylation in the Mitsunobu Reaction of 2-Pyridone”Tetrahedron Letters35(18): 2819-2822 (1994).
Cummings et al. “Plasma Ghrelin Levels After Diet-Induced Weight Loss or Gastric Bypass Surgery”New England Journal of Medicine346(21): 1623-1630 (2002).
Cunha et al. “Ghrelin and Growth Hormone (GH) Secretagogues Potentiate GH-Releasing Hormone (GHRH)-Induced Cyclic Adenosine 3′, 3′-Monophosphate Production in Cells Expressing Transfected GHRH and GH Secretagogue Receptors”Endocrinology143(12): 4570-4582 (2002).
Deghenghi et al. “GH-Releaseing Activity of Hexarelin, A New Growth Hormone Releasing Peptide, In iNfant and Adult Rats”Life Sciences54(18): 1324-1328 (1994).
Deghenghi et al. “Somatostatin Octapeptides (Lanreotide, Octreotide, Vapreotide, and their Analogs) Share the Growth Hormone-Releasing Peptide Receptor in the Human Pituitary Gland”Endocrine14(1): 29-33 (2001).
Deghenghi et al. “Targeting the Ghrelin Receptor”Endocrine22(1): 13-18 (2003).
Depoortere et al. “Interaction of the Growth Hormone-Releasing Peptides Ghrelin and Growth Hormone-Releasing Peptide-6 with the Motilin Receptor in the Rabbit Gastric Antrum”The Journal of Pharmacology and Experimental Therapeutics305: 660-667 (2003).
Devi “Heterodimerization of G-Protein-Coupled Receptors: Pharmacology, Signaling a
Fraser Graeme L.
Hoveyda Hamid
Peterson Mark L.
Ramaseshan Mahesh
Kosar Andrew D
Myers Bigel & Sibley Sajovec, PA
Tranzyme Pharma Inc.
LandOfFree
Macrocyclic modulators of the ghrelin receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Macrocyclic modulators of the ghrelin receptor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Macrocyclic modulators of the ghrelin receptor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4175041